SCM
RCKT icon

Suvretta Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Suvretta Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,992,735
Closed -$10.5M – 106
2025
Q4 		$10.5M Sell
2,992,735
-850,598
-22% -$2.91M 0.22% 61
2025
Q3 		$12.5M Sell
3,843,333
-300,000
-7% -$945K 0.32% 60
2025
Q2 		$10.2M Buy
4,143,333
+641,333
+18% +$3.25M 0.31% 54
2025
Q1 		$23.4M Buy
3,502,000
+935,049
+36% +$9.24M 0.87% 34
2024
Q4 		$32.3M Buy
+2,566,951
New +$38.6M 1.1% 32

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Suvretta Capital Management's RCKT Position: Q1 2026 in Review

Suvretta Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 2,992,735 shares — an estimated $10.5M sold.

Suvretta Capital Management first reported a position in RCKT in Q4 2024 and held it in 5 quarters. The position peaked at $32.3M in Q4 2024. 199 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Suvretta Capital Management reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Suvretta Capital Management sold 2,992,735 Rocket Pharmaceuticals shares in Q1 2026, an estimated $10.5M.
  • Suvretta Capital Management first reported a position in Rocket Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • Suvretta Capital Management's Rocket Pharmaceuticals position peaked at $32.3M in Q4 2024.
  • 199 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Suvretta Capital Management's 13F filing for Q1 2026, filed 15 May 2026.